Cardiovascular Systems Inc

Cardiovascular Systems — Merger or Acquisition (November 2008)

37 slides from Cardiovascular Systems's merger presentation, Nov 10, 2008

  1. Slide 1: The New Frontier for Treating Peripheral Arterial Disease (PAD)

    Cardiovascular Systems, Inc. The New Frontier for Treating Peripheral Arterial Disease (PAD) November 2008

  2. Slide 2: Safe Harbor Agreement: Forward-Looking Statements

    Confidential 3 Safe Harbor Agreement FORWARD-LOOKING STATEMENTS This presentation contains forward-looking information that involves significant risks and uncertainties, including those set forth in the "Risk Factors" section of CSI's Form 10 dated October 28, 2008. Forward- looking information rela

  3. Slide 3: Recent Reverse Merger Transaction Summary

    Recent Reverse Merger Transaction Summary Merging Companies Replidyne, Inc. (public shell), CSI (surviving company) Structure One-step all stock merger (S-4 to be filed) Ticker (current/proposed) NASDAQ: RDYN/CSII Ownership % Replidyne shareholders - 17%, CSI shareholders - 83% Adjusted if Net Asset

  4. Slide 4: Presenters

    Confidential 7 Presenters Dave Martin President and CEO 20 years of leadership experience in medical technology COO of FoxHollow Technologies VP of Global Sales at Rita Medical Sales and sales management at Procter & Gamble, Guidant and Boston Scientific Larry Betterley Chief Financial Officer 25 ye

  5. Slide 5: Other Key Executives

    Confidential 9 Other Key Executives James E. Flaherty Chief Administrative Officer 30 years experience in finance and administration, including 4 publicly traded companies Robert J. Thatcher Executive VP 29 years experience in sales, marketing and operations John Borrell VP of Sales 14 years experie

  6. Slide 6: Overview of Diamondback 360°

    Confidential 11 Overview of Diamondback 360° Distinguishes between plaque and healthy tissue Removes soft and calcified plaque Addresses large and growing PAD market opportunity Approximately $45MM annualized revenue (Q1 FY 2009)

  7. Slide 7: Industry Overview

    Industry Overview

  8. Slide 8: Peripheral Arterial Disease (PAD)

    Confidential 15 Circulatory problem affecting 8 -12 million people in the U.S. Peripheral Arterial Disease (PAD) Source: Journal of American Medical Association.

  9. Slide 9: U.S. Disease Prevalence Comparison

    Confidential 17 5.8 10.7 12.0 16.0 17.0 0 2 4 6 8 10 12 14 16 18 Stroke PAD CAD Diabetes Source: American Medical Association, American Heart Association and SEER Cancer Statistics Review. Cases (in millions) U.S. Disease Prevalence Comparison Cancer Note: Green denotes plaque related diseases. * Re

  10. Slide 10: PAD is a Large and Underserved Market

    Confidential 19 1st Qtr 2nd Qtr East 1.5 1 West 30.6 38.6 North 45.9 46.9 1st Qtr 2nd Qtr East 2.5 12 West 30.6 38.6 North 45.9 46.9 8.0 - 12.0 Million Potential U.S. PAD Patients 2.5 Million Diagnosed 1.5 Million Procedural Interventions PAD is a Large and Underserved Market 1.5 Million Procedural

  11. Slide 11: Prevalence of Calcium

    Confidential 21 Prevalence of Calcium Below The Knee Calcium Heavily Calcified Heavily Calcified Above The Knee Calcium 30% 70%

  12. Slide 12: Current Surgical Treatment Options

    Confidential 23 Amputations 180,000 Bypass Procedures 227,400 Current Surgical Treatment Options

  13. Slide 13: Shortcomings of Non-Atherectomy Options

    Confidential 25 Shortcomings of Non-Atherectomy Options Balloons Damage Stents Fracture

  14. Slide 14: Shortcomings of Other Atherectomy Devices

    Confidential 27 Safety Profile Do not distinguish between plaque and healthy tissue May produce large debris particles Challenged by Calcium Not effective in calcium Calcium present in 46% of all cases Treatment Time Requires multiple insertions Shortcomings of Other Atherectomy Devices

  15. Slide 15: Our Solution: The Diamondback 360°

    Our Solution The Diamondback 360°

  16. Slide 16: Diamondback 360°

    Confidential 31 Diamondback 360° 283 Hospitals 11,000 Devices Sold Since 9- 07 $11.6M Revenue-Q1 FY 2009 >90% 90-Day Re-order Rate Note: All data as of quarter ended September 2008. Strong safety profile Differential sanding lowers risk of adverse events Small particulate matter reduces risk of dist

  17. Slide 17: Orbital Atherectomy

    Confidential 33 Orbital Atherectomy

  18. Slide 18: Differential Sanding

    Confidential 35 Differential Sanding

  19. Slide 19: Small Particulate Size

    Confidential 37 Small Particulate Size 36 experiments (carbon blocks, animal and cadaver models) 93% of particles smaller than red blood cells 99% of particles smaller than lumen of capillaries

  20. Slide 20: Case Study: BTK Diamondback 360° in Action

    Confidential 39 Non-healing toe wound 60% occluded anterior tibial < 10% residual Dr Marcias @ Plaza Medical Case Study: BTK Diamondback 360°in Action Before After 60% occluded < 10% residual IVUS View

  21. Slide 21: Pre-Launch Clinical Rigor

    Confidential 41 OASIS Pivotal Trial 20 Sites 124 Patients U.S. Safety / Efficacy PAD II Feasibility Trial 7 Sites 66 Patients Europe Safety / Efficacy PAD I Feasibility Trial 2 Sites 17 Patients Europe Safety TOTAL: 207 Patients Size Demonstrated Location Trial / Study Pre-Launch Clinical Rigor

  22. Slide 22: OASIS Data

    Confidential 43 Primary efficacy endpoint Acute debulking measured angiographically 55% reduction Primary safety endpoint Cumulative number of patients with serious adverse events thru 30 days <16 % SAEs Secondary efficacy/safety endpoint TLR rate thru 6 months <20% TLR FDA Target OASIS Result 201 L

  23. Slide 23: OASIS Building on Clinical Rigor

    Confidential 45 Single and Multiple Non- Randomized Registries Single-Center Retrospective Trial Single- Center Trial Multi-Center Retrospective Trial Single-Center Randomized Prospective Multi-Center Non-Randomized Prospective Multi-Center Randomized Prospective OASIS Building on Clinical Rigor Tal

  24. Slide 24: Planned Clinical Studies

    Confidential 47 CALCIUM 360 To compare performance of Diamondback 360 to angioplasty in calcified infra-popliteal arteries. Measuring plaque reduction, dissection, adjunctive therapy and clinically driven restenosis rates. COMPLIANCE 360 To compare performance of Diamondback 360 to angioplasty in ca

  25. Slide 25: Coronary Atherectomy Comparison

    Confidential 49 Coronary Atherectomy Comparison ORBIT 1 SOLD Registry DIRECTIONAL ATHERECTOMY ROTABLATOR 17 Study Analysis Number of Pts. / Lesions 50 / 49 71 / 90 10,043 Pts. Treatment / Adjunctive Therapy DB 360 / Stent DVI / Stent Rota / PTCA Pre Treat Stenosis % 85.7 +/- 8.7 74% Not Reported Pos

  26. Slide 26: Attractive Reimbursement

    Confidential 51 Peripheral Coronary In Hospital $8,548 - $16,299 $9,468 - $13,421 $561 first artery $178 each additional Physician $480 - $543 Attractive Reimbursement Source: 2008 In-Patient Final Rule / 2008 Physician Payment Final Rule

  27. Slide 27: Core Technology Leverage

    Confidential 53 Three variables impact lumen and efficiency: Speed Crown characteristics Shaft characteristics Core Technology Leverage Provides New Products for Market Expansion Speed Increased rotational speed increases lumen Crown Characteristics Crown Mass Crown Shape Grit Height Shaft Shape Con

  28. Slide 28: Product Improvement Opportunities

    Product Improvement Opportunities Larger lumens Better efficiency Improved performance in all plaque morphologies Improved ease of use

  29. Slide 29: Product Offering Expansion Increased Sales Growth/Efficiency

    Product Offering Expansion Increased Sales Growth/Efficiency

  30. Slide 30: Financial Overview

    Financial Overview

  31. Slide 31: Strong Revenue Momentum

    Confidential 61 Strong Revenue Momentum $4.6 $7.7 $0 $2 $4 $6 Q2 08 (December) Q3 08 (March) 0 1000 2000 3000 57 107 0 50 100 Q2 Q3 1300 2300 $8 Revenue in Millions Units Sold Number of Accounts Revenue and Units Sold 4000 $10 $9.9 3100 Q4 08 (June) 184 Q4 300 150 200 283 Q109 250 $12 $11.6 3600 Q1

  32. Slide 32: Quality Revenue

    Confidential 63 Quality Revenue 20 15 0 5 10 15 20 25 Historical Actual Average Historical Target 75% >90% 0% 25% 50% 75% 100% Actual Target 90-Day Re-Order Rate Quarterly Device Usage per Account

  33. Slide 33: Strong Gross Margins

    Confidential 65 53% 67% 25% 50% Q2 08 Q3 08 Strong Gross Margins 75+% Long-Term Target 68%* Q4 08 75% 100% *Excluding charge related to new product transition. Q1 09 67%

  34. Slide 34: Operating Leverage with Increasing Sales

    75+% Confidential 67 Operating Leverage with Increasing Sales Q1 2009 (Sept) SG&A / Revenue* 114% 74% R&D / Revenue* 42% 10% Operating Margin* Unprofitable Unprofitable Targets at $150MM Rev. FoxHollow at $190MM Rev. Long-Term Targets 55% 45%-48% 15% 10%-13% Profitable 15%-20% 67% 75% 77% Gross Marg

  35. Slide 35: Balance Sheet Overview

    Confidential 69 31.4 31.4 Debt (with warrants) As of September 30, 2008 Actual Pro Forma* Cash $14.7 $52.2 Long-Term Investments 22.9 22.9 Total Assets 51.6 89.1 Shareholders' Equity 13.9 51.4 USE OF PROCEEDS: Commercial Expansion Research and Development Infrastructure for growth *Assumes middle of

  36. Slide 36: Investment Highlights

    Confidential 71 Large underserved PAD market opportunity Proven medical device management team with deep PAD knowledge Highly differentiated products - - Strong safety profile - - Effective in both soft and calcified plaque, both ATK and BTK - - Reduce treatment times and cost - - Supported by first

  37. Slide 37: Additional Information about the Merger and Where to Find It

    Confidential 73 Additional Information about the Merger and Where to Find It This communication may be deemed to be solicitation material in respect to the proposed transaction between CSI and Replidyne. In connection with the transaction, Replidyne intends to file a registration statement on Form S

Cardiovascular Systems — Merger or Acquisition (November 2008) on 6ix